Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: two randomized trials in healthy volunteers

Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: two randomized trials in healthy volunteers

Fabrizia Mariotti,1 Mirco Govoni,1 Germano Lucci,1 Debora Santoro,1 Marie Anna Nandeuil2 1Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy; 2Global Clinical Development, Chiesi S.A.S., Courbevoie, France Purpose: The purpose of this study was to evaluate safety, tolerability, and...

Full description

Bibliographic Details
Main Authors: Mariotti F, Govoni M, Lucci G, Santoro D, Nandeuil MA
Format: Article
Language:English
Published: Dove Medical Press 2018-10-01
Series:International Journal of COPD
Subjects:
Healthy volunteers
pulmonary disease
chronic obstructive
phosphodiesterase 4 inhibitors
pharmacokinetics
Online Access:https://www.dovepress.com/safety-tolerability-and-pharmacokinetics-of-single-and-repeat-ascendin-peer-reviewed-article-COPD

Internet

https://www.dovepress.com/safety-tolerability-and-pharmacokinetics-of-single-and-repeat-ascendin-peer-reviewed-article-COPD

Similar Items